MONTVALE, N.J., Oct. 21, 2008 (GLOBE NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electroceutical(r) therapy systems designed to target and enhance the body's anti-inflammatory and angiogenic responses, today commented on NASDAQ's October 16, 2008 announcement that it had implemented a temporary suspension of the $1.00 minimum bid price requirement until January 19, 2009. As a result of the rule suspension by NASDAQ, Ivivi will now have until July 2, 2009 to regain compliance with the minimum $1.00 share bid price requirement instead of the previously reported date of March 30, 2009.
